Spyre Therapeutics Files 8-K, Name Change Confirmed
Ticker: SYRE · Form: 8-K · Filed: May 30, 2024 · CIK: 1636282
| Field | Detail |
|---|---|
| Company | Spyre Therapeutics, Inc. (SYRE) |
| Form Type | 8-K |
| Filed Date | May 30, 2024 |
| Risk Level | low |
| Pages | 2 |
| Reading Time | 2 min |
| Key Dollar Amounts | $0.0001 |
| Sentiment | neutral |
Sentiment: neutral
Topics: name-change, corporate-action
TL;DR
Spyre Therapeutics (fka Aeglea) filed an 8-K, confirming name change and address.
AI Summary
Spyre Therapeutics, Inc. (formerly Aeglea BioTherapeutics, Inc.) filed an 8-K on May 30, 2024, to report a current event. The filing does not disclose specific details about the event itself, but it confirms the company's name change and its principal executive offices located at 221 Crescent Street, Building 23, Suite 105, Waltham, Massachusetts.
Why It Matters
This filing formally documents the name change of the company, which may signal a strategic shift or rebranding effort.
Risk Assessment
Risk Level: low — The filing is procedural and does not contain information that inherently increases or decreases risk.
Key Players & Entities
- Spyre Therapeutics, Inc. (company) — Registrant
- Aeglea BioTherapeutics, Inc. (company) — Former company name
- May 30, 2024 (date) — Date of report
- 221 Crescent Street Building 23 Suite 105 (location) — Principal executive offices
- Waltham, Massachusetts (location) — City and State of principal executive offices
FAQ
What is the primary purpose of this 8-K filing for Spyre Therapeutics, Inc.?
The primary purpose is to report a current event as required by the SEC, and to formally document the company's name change from Aeglea BioTherapeutics, Inc.
When was the earliest event reported in this filing?
The earliest event reported was on May 30, 2024.
What was Spyre Therapeutics, Inc. formerly known as?
Spyre Therapeutics, Inc. was formerly known as Aeglea BioTherapeutics, Inc.
Where are Spyre Therapeutics, Inc.'s principal executive offices located?
The principal executive offices are located at 221 Crescent Street, Building 23, Suite 105, Waltham, Massachusetts, 02453.
Under which section of the Securities Exchange Act of 1934 is this report filed?
This report is filed pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934.
Filing Stats: 523 words · 2 min read · ~2 pages · Grade level 13.3 · Accepted 2024-05-30 16:33:56
Key Financial Figures
- $0.0001 — nge on which registered Common stock, $0.0001 Par Value SYRE The Nasdaq Global Se
Filing Documents
- d806070d8k.htm (8-K) — 23KB
- 0001193125-24-150395.txt ( ) — 145KB
- syre-20240530.xsd (EX-101.SCH) — 3KB
- syre-20240530_lab.xml (EX-101.LAB) — 18KB
- syre-20240530_pre.xml (EX-101.PRE) — 11KB
- d806070d8k_htm.xml (XML) — 4KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Date: May 30, 2024 SPYRE THERAPEUTICS, INC. By: /s/ Cameron Turtle Cameron Turtle Chief Executive Officer